Jan 31, 2025 · The participants in HYPERION (NCT04811092) can now all choose to be treated with Winrevair as part of the open-label extension study SOTERIA (NCT04796337), according to the developer.. The decision to end the trial early was based on new positive data from another Phase 3 trial of Winrevair — early results that Merck said made continuing HYPERION unnecessary, and also not helpful for its ...

Oct 9, 2024 · Approved treatments for people with PH-ILD lacking in many countries. In a previous Phase 1 study (NCT04041648) assessing L606’s pharmacokinetics — its movement into, through, and out of the body — in healthy adults, the treatment showed therapeutic levels for up to 12 hours, with a blood plasma peak concentration seven times lower than Tyvaso, the company reported.

4 days ago · The Phase 1B trial, which began enrolling last spring, is designed to assess TX45 in people with Group 2 PH, including PH-HFpEF (Part A) and PH-HFrEF (Part B), where the left ventricle is too weak to pump blood effectively.. Heart function and hemodynamics are being measured before and for eight hours after a dose of TX45 (0.3 mg/kg, 1 mg.kg, or 3 mg/kg) via infusion into the bloodstream.

Jan 29, 2025 · The analysis revealed that men with PAH had a significantly larger mean right heart size than women, both in the right atrial area (21.76 vs. 17.65 square centimeters, cm 2) and right ventricular area (24.02 vs. 18.93 cm 2).These differences were consistent throughout all WHO functional classes, except for the right atrial area in WHO functional class 4, which was similar between the sexes.

Jan 29, 2025 · Right heart size differs between men and women with PAH: Study. Men with pulmonary arterial hypertension (PAH) have a larger right heart size and worse survival rates than women, independent of body size and functional status, a study reports.

Aug 22, 2018 · “Mylan has a strong history of leading the way in creating important access to generic medicines, and we’re excited to continue that tradition by offering the first generic to Adcirca Tablets,” Heather Bresch, CEO of Mylan, said in a press release.. “Mylan offers more than 650 products in the U.S., and the addition of Tadalafil Tablets strengthens our …

Dec 16, 2024 · An oxygen-sensing protein called hypoxia-inducible factor-1alpha, or HIF-1alpha, may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible therapeutic target for people with this rare type of pulmonary hypertension, a study by …

ALG-801 found safe, well tolerated in Phase 1 study, per developer. PAH is caused by the narrowing of the pulmonary arteries — the blood vessels that carry blood through the lungs — which restricts blood flow and causes high blood pressure, or hypertension. It also makes the heart work harder to pump blood through the body, which can lead to right heart failure in advanced disease stages.

Jan 22, 2025 · People with pulmonary arterial hypertension (PAH) seen to be at an intermediate risk of death — whether in the low or high range of that middle-level risk — were more likely to have better outcomes when treated with Adempas (riociguat) than given a placebo in a Phase 3 clinical trial, its data show.

Jan 17, 2025 · The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This regimen is “well-justified based on the totality of the observed safety and efficacy data from Phase ...